Metropolis Healthcare
1,866.00
+6.60(+0.35%)
Market Cap₹9,666.23 Cr
PE Ratio66.39
Company Performance:
1D+0.35%
1M+8.63%
6M-7.92%
1Y-8.63%
5Y+31.39%
View Company Insightsright
More news about Metropolis Healthcare
08Apr 25
Metropolis Healthcare Expands Footprint in North India with Strategic Acquisition in Dehradun
Metropolis Healthcare's subsidiary is set to acquire Dr. Ahujas' Pathology and Imaging Centre in Dehradun, Uttarakhand for ₹35 crore. The acquisition, expected to complete within 45 days, aims to strengthen Metropolis's presence in North India. This strategic move aligns with the company's expansion plans, enhancing its diagnostic capabilities in the region and capitalizing on the growing healthcare needs in tier-2 cities.
07Apr 25
Metropolis Healthcare Expands North India Presence with ₹35.01 Crore Acquisition of Dehradun's DAPIC
Metropolis Healthcare's subsidiary has acquired Dr. Ahujas' Pathology and Imaging Centre (DAPIC) in Dehradun for ₹35.01 crore in an all-cash deal. DAPIC, founded in 1990, is a leading diagnostic chain in Uttarakhand with NABL and NABH accredited labs. This acquisition is part of Metropolis' 'String of Pearls' strategy to expand in North India, increasing their revenue contribution from the region to 14-15%. The deal positions Metropolis as the second-largest diagnostic chain in Uttarakhand's ₹500 crore market.
09Mar 25
Metropolis Healthcare Expands North India Footprint with Strategic Acquisition
Metropolis Healthcare announces plans to acquire Scientific Pathology, an Agra-based diagnostic service provider, for a valuation between Rs 55 crore and Rs 83 crore. The deal, expected to close by March-end, aims to strengthen Metropolis' presence in Western Uttar Pradesh and North India. This strategic move follows the company's recent acquisition of Delhi-based Core Diagnostics, aligning with the ongoing consolidation trend in India's diagnostic services sector.
03Mar 25
Metropolis Healthcare Expands Footprint in Western UP with Strategic Acquisition
Metropolis Healthcare's subsidiary is acquiring Agra-based Scientific Pathology for ₹55-83 crore, strengthening its presence in Western Uttar Pradesh. The deal involves acquiring all labs and collection centers of Scientific Pathology in Agra and nearby towns. This move aims to establish Agra as a regional reference lab, accelerate B2C expansion, and enhance access to advanced diagnostics in the region. Scientific Pathology, founded in 1984, has a strong B2C focus with 90% revenue from walk-in patients and a FY24 turnover of ₹26 crore.
Metropolis Healthcare
1,866.00
+6.60
(+0.35%)
1 Year Returns:-8.63%
Industry Peers
Dr. Lal Path Labs
2,880.00
(+0.89%)
Vijaya Diagnostic Centre
1,002.00
(-0.80%)
Metropolis Healthcare
1,866.00
(+0.35%)
Thyrocare Technologies
1,068.40
(-0.35%)
Krsnaa Diagnostics
779.45
(+5.25%)
Suraksha Diagnostic
320.20
(-0.87%)
3B BlackBio DX
1,599.00
(-0.90%)
Sastasundar Ventures
280.05
(-1.56%)
Choksi Laboratories
182.00
(-0.36%)